April 2017

Phase III Trial to Examine Veliparib in BRCA Positive Breast Cancer

April 19, 2017

Clinical Trials in Progress

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.